Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des maladies de l'Appareil Digestif, Hôtel Dieu, CHU Nantes, France; Université de Nantes, France.
CHU de Nantes, INSERM, CIC 1413, Pôle Hospitalo-Universitaire 11: Santé Publique, Santé au Travail, Pharmacie, Stérilisation, Clinique des Données, France.
Surgery. 2021 Sep;170(3):727-735. doi: 10.1016/j.surg.2021.02.048. Epub 2021 Mar 30.
Tertiary hyperparathyroidism occurs in 25% to 50% of kidney-transplanted patients. Indication of parathyroidectomy is now discussed, since the calcimimetic agent, cinacalcet, is an alternate option. The effects of either of these treatments on graft function remain controversial, studied only in small cohorts showing either decrease or absence of modification. We performed a meta-analysis to evaluate the evolution of graft function after surgical or medical treatment.
Studies assessing graft function in tertiary hyperparathyroidism after parathyroidectomy or cinacalcet introduction were enrolled into quantitative analysis using Pubmed, Embase, and Cochrane databases following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis reporting guidelines. Among 68 screened studies, 18 had no missing data and were included for statistical analyses. We performed random effect meta-analysis to determine changes in serum creatinine and estimated glomerular filtration rate.
Seven studies assessing the evolution of graft function 6 and/or 12 months after parathyroidectomy and 13 after administration of cinacalcet were included. Meta-analysis found no significant variations after parathyroidectomy in serum creatinine (6 studies, 314 patients) and estimated glomerular filtration rate (2 studies, 105 patients). No significant variation was found after administration of cinacalcet in serum creatinine (10 studies, 404 patients) and estimated glomerular filtration rate (6 studies, 149 patients). A significant heterogeneity between the studies (P < .01, Cochran's Q) was found.
Meta-analysis shows that parathyroidectomy and cinacalcet do not significantly impair graft function in patients with tertiary hyperparathyroidism. However, the significant heterogeneity between selected studies, partially explained by the lack of consensual definition of tertiary hyperparathyroidism, limits the conclusions of all previously published series.
甲状旁腺功能亢进症在 25%至 50%的肾移植患者中发生。由于有钙敏感受体激动剂西那卡塞作为替代选择,因此现在正在讨论甲状旁腺切除术的适应证。这两种治疗方法对移植物功能的影响仍存在争议,仅在显示减少或无改变的小队列研究中进行了研究。我们进行了一项荟萃分析,以评估手术或药物治疗后移植物功能的演变。
根据系统评价和荟萃分析报告的首选报告项目指南,使用 Pubmed、Embase 和 Cochrane 数据库对评估甲状旁腺功能亢进症手术后或西那卡塞引入后移植物功能的研究进行定量分析。在筛选的 68 项研究中,有 18 项没有缺失数据,并纳入了统计分析。我们进行了随机效应荟萃分析,以确定血清肌酐和估计肾小球滤过率的变化。
纳入了 7 项评估甲状旁腺切除术 6 个月和/或 12 个月后移植物功能演变的研究,以及 13 项评估西那卡塞给药后移植物功能演变的研究。荟萃分析发现,甲状旁腺切除术后血清肌酐(6 项研究,314 例患者)和估计肾小球滤过率(2 项研究,105 例患者)无显著变化。西那卡塞给药后血清肌酐(10 项研究,404 例患者)和估计肾小球滤过率(6 项研究,149 例患者)也无显著变化。研究之间存在显著的异质性(P<.01,Cochran's Q)。
荟萃分析表明,甲状旁腺切除术和西那卡塞不会显著损害甲状旁腺功能亢进症患者的移植物功能。然而,所选研究之间存在显著的异质性,部分原因是缺乏对甲状旁腺功能亢进症的共识定义,限制了所有先前发表的系列研究的结论。